Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, and Domainex Ltd., a small-molecule drug discovery company based in Cambridge, the UK, have formed a collaboration to provide integrated small-molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the UK and beyond with target-to-lead identification, optimization, safety/toxicology, pre-clinical and clinical API supply services.

Domainex is a provider of small-molecule drug-discovery services that complement the pre-clinical to commercial range of services provided by Johnson Matthey Fine Chemicals' Custom Pharma Solutions offering in Europe. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex's target-to-lead identification and optimization capabilities, and will then be able to transfer their projects directly to Johnson Matthey, using its Pharmorphix solid state services for salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture.

Source: Domainex